The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse garadacimab (Andembry®) from the basic healthcare package. This medicinal product can be used for patients with hereditary angioedema (HAE). This is a hereditary disease, in which a person experiences attacks of severe swelling of the skin and mucous membranes. If the Minister adopts our advice, garadacimab will be included in the Medicine Reimbursement System (GVS). Only then will this medicinal product be reimbursed from the healthcare insurer's basic healthcare package.
Current state of affairs: advisory report sent to the Minister
The National Health Care Institute has sent this advice to the Minister of VWS. The Minister makes the final decision whether or not to reimburse the medicinal product from the basic healthcare package.
Garadacimab is intended to prevent attacks of swelling in certain people
Garadacimab is the active substance. The brand name is Andembry®. The medicine is an injection, injected under the skin once a month.
It can be used in people with hereditary angioedema (HAE). HAE is a hereditary disease in which someone has attacks of swelling that have a rapid onset. This swelling is also called oedema. It can occur in different places in the body, for example in the skin, abdomen, throat or mouth. The cause of the swelling is a leak in the blood vessels due to a gene change.
Advice of the National Health Care Institute on the reimbursement of garadacimab
The National Health Care Institute advises the Minister of Health, Welfare and Sport to reimburse garadacimab (Andembry®) from the basic healthcare package. The recommendation is to include the medicinal product in List 1A of the GVS in a newly formed cluster with lanadelumab (Takhzyro®). The price of garadacimab should also not exceed the price of lanadelumab.
For more information on the GVS and the Lists 1A, 1B and 2, see page ‘Reimbursement of outpatient medicines’.
More information or questions?
If you have any questions about this advice, please send your question to the National Health Care Institute via warcg@zinl.nl. If you have questions about the reimbursement of a medicinal product, the personal expenses or whether you should pay a contribution, please ask your health insurance provider.
How did the advice come about?
The Minister of VWS asks the National Health Care Institute to make an assessment. The Minister makes the final decision whether or not to reimburse the medicinal product from the basic healthcare package.
Explanation about the reimbursement of medicinal products
Garadacimab is an extramural medicinal product. Extramural means: medicines for home use that can be obtained at the pharmacy with the prescription from a physician. They are only reimbursed from the basic healthcare package if they are listed in the GVS.